For how we live.
A government-funded test-negative study put effectiveness at 86% against emergency visits and 88% against intensive care, though the smallest subgroups carried wide confidence intervals.
A test-negative study across seven paediatric hospitals in Ontario and Quebec, run after a publicly funded rollout, estimated 78% effectiveness against laboratory-confirmed RSV and 97% against intensive-care admission.
The SMART trial tested clesrovimab against palivizumab in premature and heart- and lung-affected infants. It was built to show safety, not to prove one prevents more RSV than the other.